Cargando…

Pilot study of a new freely available computer-aided polyp detection system in clinical practice

PURPOSE: Computer-aided polyp detection (CADe) systems for colonoscopy are already presented to increase adenoma detection rate (ADR) in randomized clinical trials. Those commercially available closed systems often do not allow for data collection and algorithm optimization, for example regarding th...

Descripción completa

Detalles Bibliográficos
Autores principales: Lux, Thomas J., Banck, Michael, Saßmannshausen, Zita, Troya, Joel, Krenzer, Adrian, Fitting, Daniel, Sudarevic, Boban, Zoller, Wolfram G., Puppe, Frank, Meining, Alexander, Hann, Alexander
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9167159/
https://www.ncbi.nlm.nih.gov/pubmed/35543874
http://dx.doi.org/10.1007/s00384-022-04178-8
Descripción
Sumario:PURPOSE: Computer-aided polyp detection (CADe) systems for colonoscopy are already presented to increase adenoma detection rate (ADR) in randomized clinical trials. Those commercially available closed systems often do not allow for data collection and algorithm optimization, for example regarding the usage of different endoscopy processors. Here, we present the first clinical experiences of a, for research purposes publicly available, CADe system. METHODS: We developed an end-to-end data acquisition and polyp detection system named EndoMind. Examiners of four centers utilizing four different endoscopy processors used EndoMind during their clinical routine. Detected polyps, ADR, time to first detection of a polyp (TFD), and system usability were evaluated (NCT05006092). RESULTS: During 41 colonoscopies, EndoMind detected 29 of 29 adenomas in 66 of 66 polyps resulting in an ADR of 41.5%. Median TFD was 130 ms (95%-CI, 80–200 ms) while maintaining a median false positive rate of 2.2% (95%-CI, 1.7–2.8%). The four participating centers rated the system using the System Usability Scale with a median of 96.3 (95%-CI, 70–100). CONCLUSION: EndoMind’s ability to acquire data, detect polyps in real-time, and high usability score indicate substantial practical value for research and clinical practice. Still, clinical benefit, measured by ADR, has to be determined in a prospective randomized controlled trial. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s00384-022-04178-8.